These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18173809)

  • 1. Better management of patients with overactive bladder with antimuscarinics?
    MacDiarmid S
    Int J Clin Pract; 2008 Jan; 62(1):3-4. PubMed ID: 18173809
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In brief: Oxytrol OTC.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):76. PubMed ID: 24662958
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Costantini E; Lazzeri M
    Eur Urol; 2010 Jan; 57(1):152-3. PubMed ID: 19446952
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Soljanik I
    Eur Urol; 2010 Jan; 57(1):153. PubMed ID: 19446950
    [No Abstract]   [Full Text] [Related]  

  • 6. Gelnique (oxybutynin chloride) 10% gel for overactive bladder.
    Lajiness MJ
    Urol Nurs; 2010; 30(4):253-4. PubMed ID: 20949812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [High patient satisfaction with the transdermal system].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):27. PubMed ID: 23646401
    [No Abstract]   [Full Text] [Related]  

  • 8. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
    Staskin DR; Robinson D
    Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder.
    Herschorn S; Vicente C; Piwko C
    J Med Econ; 2010; 13(3):508-15. PubMed ID: 20690893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Rufus Cartwright and Linda Cardozo. Transdermal oxybutynin: sticking to the facts. Eur urol 2007;51:907-14.
    Cornel EB
    Eur Urol; 2007 Jul; 52(1):286-7; author reply 287. PubMed ID: 17434252
    [No Abstract]   [Full Text] [Related]  

  • 12. Oxybutynin gel for the treatment of overactive bladder.
    Gomelsky A; Dmochowski RR
    Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
    Ho C
    Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxybutynin in detrusor overactivity.
    Diokno A; Ingber M
    Urol Clin North Am; 2006 Nov; 33(4):439-45, vii. PubMed ID: 17011379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hyperhidrosis with oxybutynin.
    Schollhammer M; Misery L
    Arch Dermatol; 2007 Apr; 143(4):544-5. PubMed ID: 17438194
    [No Abstract]   [Full Text] [Related]  

  • 16. Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 May; 107(10):1612-7. PubMed ID: 21070569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial comment.
    de Jong TP
    J Urol; 2009 Oct; 182(4 Suppl):2038; discussion 2039. PubMed ID: 19695627
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment.
    Jorgensen TM
    J Urol; 2009 Oct; 182(4 Suppl):2038; discussion 2039. PubMed ID: 19695626
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment.
    Yang SS
    J Urol; 2009 Oct; 182(4 Suppl):2038-9; discussion 2039. PubMed ID: 19695625
    [No Abstract]   [Full Text] [Related]  

  • 20. Idiopathic urgency urinary incontinence.
    Keller DL
    N Engl J Med; 2010 Dec; 363(27):2672; author reply 2672. PubMed ID: 21190469
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.